Trial Information
Current as of July 02, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score \>39 age \>39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate
- • -
- • Exclusion Criteria:known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance
- • -
About Institute Of Psychiatry, London
The Institute of Psychiatry, London, is a leading research institution dedicated to advancing the field of mental health through innovative clinical trials and studies. Renowned for its commitment to excellence in psychiatric research, the institute collaborates with a diverse range of academic, clinical, and industry partners to explore new therapeutic interventions and improve patient outcomes. With a focus on evidence-based practices, the Institute of Psychiatry leverages cutting-edge methodologies and interdisciplinary approaches to address complex mental health challenges, contributing significantly to the global understanding and treatment of psychiatric disorders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Newcastle Upon Tyne, , United Kingdom
Oxford, , United Kingdom
Southampton, , United Kingdom
Swindon, , United Kingdom
Patients applied
Trial Officials
Robert Howard
Principal Investigator
Institute of Psychiatry, London
Peter Bentham
Principal Investigator
Queen Elizabeth Psychiatric Hospital, Birmingham
Richard Brown
Principal Investigator
Institute of Psychiatry, London
Roger Bullock
Principal Investigator
Kingshill Research Centre, Victoria Hospital, Swindon
Alistair Burns
Principal Investigator
Wythenshawe Hospital, Manchester
Clive Holmes
Principal Investigator
Moorgreen Hospital, Southampton
Robin Jacoby
Principal Investigator
Warneford Hospital, Oxford
James Lindesay
Principal Investigator
Leicester General Hospital, Leicester
John O'Brien
Principal Investigator
Newcastle General Hospital, Newcastle
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials